Type of vaccine | Reference ID | Register | Phase | Vaccine | Comparator | Sample size | Participants/centre/location |
RNA‐based vaccine | Roozen 2021 | NL9275 | 1‐2 | mRNA‐1273 20 μg ID | mRNA‐1273 20 μg IM | 30 | Healthy adults/single centre/the Netherlands |
Low 2021 | NCT04480957 | 1‐2 | ARCT‐021 (1 μg; 5 μg; 7.5 μg; 10 μg) |
Placebo | 106 | Healthy adults/single centre/Singapore | |
Li 2021b | ChiCTR2000034825 NCT04523571 |
1 | BNT162b1 10 μg | BNT162b1 30 μg | 144 | Healthy young adults/single centre/China | |
Mulligan 2020 | NCT04368728 | 1‐2 | BNT162b1 (10 μg; 30 μg; 100 μg) | Placebo | 45 | Healthy adults/2 centres/USA | |
Non‐replicating viral vector | Ramasamy 2020 | NCT04400838; ISRCTN, 15281137 | 2/3 | ChAdOx1 (2.2 × 1010 vp; 1 or 2 doses) | MenACWY | 300 | Healthy adults/2 centres/UK |
Inactivated virus | Wu 2021c | NCT04552366 | 1 | Ad5‐nCoV 0.2 mL neb 2D | Ad5‐nCoV (0.1 mL neb 2D; 0.5 mL IM + 0.2 mL neb; 0.5 mL IM; 1.0 mL IM) | 130 | Adults/single centre/China |
Zhu 2020 | NCT04341389 | 2 | Ad5‐vectored (1 × 1011 vp; 5 × 1010 vp) | Placebo | 508 | Healthy young adults/single centre/China | |
Zhu 2022 | NCT04566770 | 2 | Ad5‐vectored (3 × 1010 vp) | Placebo | 400 | Healthy children and adolescents/single centre/China | |
Che 2021 | NCT04412538 | 2 | KMS‐1 (100 EU; 150 EU) D0/14; D0/28 KMS‐1 |
Placebo | 750 | Healthy adults/2 centres/China | |
Lazarus 2021 | NCT04671017, ISRCTN 82411169 | 1‐2 | VL A2001 3 AU |
VL A2001 35 AU; 7 AU | 153 | Healthy adults/4 centres/UK | |
Pan 2021a | NCT04758273 | 1 | KCONVAC 5 μg | KCONVAC 10 μg | 60 | Healthy adults/single centre/China | |
Pan 2021a | NCT04756323 | 2 | KCONVAC (5 μg; 10 μg) (D0/14; D0/28) |
Placebo | 500 | Healthy adults/single centre/China | |
Pitisuttithum 2021 | NCT04764422 | 1 | NDV‐HXP‐S (1 μg; 1 μg + CpG1018; 3 μg; 3 μg + CpG1018; 10 μg) | Placebo | 210 | Healthy adults/single centre/Thailand | |
Pu 2021 | NCT04412538 | 1 | KMS‐1 100 EU D0/14; D0/28 | Placebo | 192 | Healthy adults/single centre/China | |
Zakarya 2021 | NCT04530357 | 1 | QazCovid‐in | Placebo | 44 | Healthy adults/single centre/Kazakhstan | |
Protein subunit | Chappell 2021 | NCT04495933 | 1 | SARS‐CoV‐2 Sclamp (5 μg; 15 μg; 45 μg) |
Placebo | 120 | Healthy adults/single centre/Australia |
Goepfert 2021 | NCT04537208 | 1‐2 | CoV2 preS dTM LD + AFO3 CoV2 preS dTM LD + ASO3 CoV2 preS dTM HD + AFO3 CoV2 preS dTM HD + ASO3 CoV2 preS dTM HD |
Placebo | 271 | Healthy adults/10 centres/USA | |
Hsieh 2021 | NCT04695652 | 2 | MVC‐COV1901 | Placebo | 3854 | Healthy adults/11 centres/Taiwan | |
Zhang 2021b | ChiCTR2100045108 | 1 | V‐01 (10 μg; 25 μg; 50 μg) | Placebo | 180 | Healthy adults/single centre/China | |
Meng 2021b | NCT04530656 | 1 | Sf9 cells vaccine (low dose in 2 doses; high dose in 2 or 3 doses) | Placebo | 168 | Healthy adults/single centre/China | |
Meng 2021b | NCT04640402 | 2 | Sf9 cells vaccine (low dose or high dose in 2 or 3 doses) | Placebo | 960 | Healthy adults/single centre/China | |
Nguyen 2021 | NCT04683484 | 2 | Nanocovax (25 μg; 50 μg; 75 μg) |
Placebo | 560 | Healthy adults/2 centres/Vietnam | |
Nguyen 2021 | NCT04683484 | 1 | Nanocovax (25 μg; 50 μg) |
Nanocovax 75 μg | 60 | Healthy adults/2 centres/Vietnam | |
Richmond 2021 | NCT04405908 | 1 | SCB‐2019 (3 μg; 3 μg + AS03; 3 μg + CpG/Alum; 9 μg; 9 μg + AS03 9 μg + CpG/Alum; 30 μg; 30 μg + AS03; 30 μg + CpG/Alu) |
Placebo | 151 | Healthy adults/single centre/Australia | |
Ryzhikov 2021 | NCT04527575 | 2 | EpiVacCorona | Placebo | 86 | Healthy adults/single centre/Russia | |
Shu 2021 | ChiCTR2100045107 | 2 | V‐01 (10 μg; 25 μg; 50 μg) | Placebo | 880 | Healthy adults/single centre/China | |
Sridhar 2021 | NCT04762680 | 2 | CoV2 preS dTM (15 µg; 10 µg) | CoV2 preS dTM 5 µg | 722 | Adults with and without prior SARS‐CoV‐2 infection and risk factors for severe disease/20 centres/USA and Honduras | |
Yang 2021 | NCT04466085 | 2 | ZF2001 (25 μg 2 doses; 50 μg 2 doses; 25 μg 3 doses; 50 μg 3 doses) | Placebo | 900 | Healthy adults/single centre/China | |
Yang 2021 |
NCT04445194 | 2 | ZF2001 (25 μg 3 doses; 50 μg 3 dose) | Placebo | 50 | Healthy adults/single centre/China | |
DNA‐based vaccine | Mammen 2021 | NCT04642638 | INO‐4800 (1 mg; 2 mg) D0/28 |
Placebo | 201 | Healthy adults/19 centres/USA | |
Virus‐like particle (VLP) | Gobeil 2021 | NCT04636697 | CoVLP 3.75 μg + AS03 | Placebo | 753 | Healthy adults/multiple centres/Canada and USA | |
Ward 2021b | NCT04450004 | CoVLP (3.75 μg with CpG1018, AS03 or without adjuvant; 7.5 μg with CpG1018, AS03 or without adjuvant; 15 μg with CpG1018, AS03 or without adjuvant) | Placebo | 180 | Canada |